How measurement and monitoring will wake physicians up to their dangerous, unnecessary, (and unintentional) prescribing habits.

Partner, Health Services, Oliver Wyman

There's big buzz around consumer behavior driving outcomes. But clinical data doesn't yet align with behavioral data.

Partner, Health & Life Sciences, Oliver Wyman

Q&A with the Academy of Nutrition and Dietetics on malnutrition's greatest challenges and opportunities

What if your doctor handed out grocery lists, not a grocery list of pills to take?

Chief Science Officer, Academy of Nutrition and Dietetics
Director, Oliver Wyman Health Innovation Center, Oliver Wyman

Pharma companies and providers in search of better solutions must look to the patient experience for answers.

Partner, Digital & Analytics, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health and Life Sciences, Oliver Wyman
Senior Knowledge Expert, Oliver Wyman

Insights in your inbox

Subscribe

2018 was a big year for industry news. Here's what might happen next in artificial intelligence, the 2020 presidential election, pharma, and more.

Global Leader, Health and Life Sciences, Oliver Wyman
Managing Partner, Americas, Oliver Wyman

Some of our 2018 predictions on consolidation, pharma, and investment came true, while others were less predictable.

Director, Marsh & McLennan Advantage, Healthcare

Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.

Partner, Health Services, Oliver Wyman
Professor of Surgery and Health Policy, Johns Hopkins Medicine
Principal, Health and Life Sciences, Oliver Wyman

Seeing a return on investment in pharma marketing means understanding what happens to every dollar.

Principal, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Digital & Analytics, Oliver Wyman

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

Insights in your inbox

Subscribe
Load More